Literature DB >> 15333799

Abdominal aortic aneurysms at multi-detector row helical CT: optimization with interactive determination of scanning delay and contrast medium dose.

Lisa M Ho1, Rendon C Nelson, John Thomas, Edgardo I Gimenez, David M DeLong.   

Abstract

PURPOSE: To prospectively evaluate a technique for optimizing aortoiliac enhancement at multi-detector row helical computed tomography (CT) with both the scanning delay and contrast medium dose determined by using an interactive method.
MATERIALS AND METHODS: Forty-five patients with abdominal aortic aneurysm were randomized to undergo multi-detector row helical CT with either an interactive protocol (n = 23) or a standard protocol (n = 22). Scanning delays in all patients were determined with automated triggering. Patients in the standard protocol group received 150 mL of contrast medium intravenously at 4 mL/sec. The same injection rate was used for the interactive protocol group, but the dose was reduced with discontinuation of injection at start of scanning. Quantities of contrast medium used and contrast-enhanced aortic attenuation achieved were compared. Aortoiliac enhancement was evaluated qualitatively by using a five-point scale (1 = poor, 5 = excellent). Quantitative and qualitative data were analyzed with the two-tailed t test and Wilcoxon rank sum test, respectively, to determine significance of differences (P <.05).
RESULTS: Data from six patients were excluded because of technical errors. Data were analyzed from 20 patients in the interactive protocol group and 19 in the standard protocol group. Mean contrast medium volume was 107 mL +/- 20 (standard deviation) in the interactive protocol group and 148 mL +/- 3 in the standard protocol group (P <.001). Mean contrast-enhanced attenuation at initial, peak, and final measurements was 257 HU +/- 38, 285 HU +/- 46, and 269 HU +/- 54, respectively, for the interactive protocol group, and 261 HU +/- 65, 288 HU +/- 66, and 269 HU +/- 61 for the standard protocol group (P >.05). Mean qualitative enhancement scores for interactive and standard protocol groups were 4.47 and 4.44, respectively (P =.47).
CONCLUSION: The interactive method is a simple, efficient, and reproducible way to optimize aortoiliac enhancement while reducing contrast medium dose. Copyright RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333799     DOI: 10.1148/radiol.2323031006

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Multi-detector row CT of the head and neck: comparison of different volumes of contrast material with and without a saline chaser.

Authors:  Dae Young Yoon; Su Yeon You; Chul Soon Choi; Suk Ki Chang; Eun Joo Yun; Young Lan Seo; Sang Joon Park; Yu-Jin Lee; Jeung Hee Moon; Young-Soo Rho; Jin-Hwan Kim
Journal:  Neuroradiology       Date:  2006-09-15       Impact factor: 2.804

2.  Spectrum of Abdominal Aortic Disease in a Tertiary Health Care Setup: MDCT Based Observational Study.

Authors:  Dg Santosh Kumar; Venkatraman Bhat; Karthik Gadabanahalli; Arjun Kalyanpur
Journal:  J Clin Diagn Res       Date:  2016-11-01

3.  Contrast Volume for Preoperative CT Angiography of the Aorta Based on Patient Heart Rate and Body Surface Area: A Pilot Study.

Authors:  Dominic Raymakers; Adriana Dubbeldam; Walter Coudyzer; Hilde Bosmans; Geert Maleux
Journal:  J Belg Soc Radiol       Date:  2019-10-04       Impact factor: 1.894

4.  64-Slice CT angiography of the abdominal aorta and abdominal arteries: comparison of the diagnostic efficacy of iobitridol 350 mgI/ml versus iomeprol 400 mgI/ml in a prospective, randomised, double-blind multi-centre trial.

Authors:  Christian Loewe; Christoph R Becker; Riccardo Berletti; Carlo Alberto Cametti; Jerome Caudron; Walter Coudyzer; Johan De Mey; Massimo Favat; Jean-François Heautot; Sam Heye; Markus Hittinger; Antoine Larralde; Jean-Pierre Lestrat; Roberto Marangoni; Koenraad Nieboer; Peter Reimer; Martin Schwarz; Melanie Schernthaner; Johannes Lammer
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.